Patents by Inventor Eric J. Toone

Eric J. Toone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210206715
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: March 19, 2021
    Publication date: July 8, 2021
    Applicants: Duke University, The University of North Carolina at Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Patent number: 11034649
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: June 15, 2021
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Patent number: 10647664
    Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: May 12, 2020
    Assignees: Duke University, University of North Carolina
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Patent number: 10597361
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: March 24, 2020
    Assignee: Duke University
    Inventors: Pei Zhou, Eric J. Toone
  • Patent number: 10550074
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: February 4, 2020
    Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Publication number: 20190367446
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: April 25, 2017
    Publication date: December 5, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Publication number: 20190169114
    Abstract: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas, Ramesh Gopalaswamy, Xiaofei Liang, Frank Navas, III
  • Patent number: 10189786
    Abstract: Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, Y, Z, X, R12, R17, R18, R19, Y1, Z1, X1, and X2 are defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as Neisseria gonorrhoeae bacterial infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: January 29, 2019
    Assignees: DUKE UNIVERSITY, UNIVERSITY OF NORTH CAROLINA
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20180169433
    Abstract: Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.
    Type: Application
    Filed: January 22, 2018
    Publication date: June 21, 2018
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Eric J. Toone, David Gooden, Frederic A. Bourke, JR., Harold Walder
  • Patent number: 9908851
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: March 6, 2018
    Assignees: Duke University, University of North Carolina Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20170349544
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 21, 2017
    Publication date: December 7, 2017
    Inventors: Pei Zhou, Eric J. Toone
  • Patent number: 9738604
    Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: August 22, 2017
    Assignee: Duke University
    Inventors: Pei Zhou, Eric J. Toone
  • Publication number: 20170113061
    Abstract: Psoralen compounds of compounds having formulae 1A-10A, 1B-10B, 1C-10C, 1D-10D, 1E-10E, 1F-10F, 1G-10G, and 1H-5H as shown in FIG. 1, and pharmaceutically acceptable salts thereof; and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an auto vaccine effect in a subject using the method.
    Type: Application
    Filed: June 18, 2015
    Publication date: April 27, 2017
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Eric J. TOONE, David GOODEN, Frederic A. BOURKE, JR., Harold WALDER
  • Publication number: 20160331731
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 17, 2016
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle XIA, David Gooden, Erik J. Soderblom, Eric J. Toone, Neil L. Spector, Wayne F. Beyer, JR., Harold Walder
  • Patent number: 9439897
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: September 13, 2016
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle Xia, David Gooden, Erik J. Soderblom, Eric J. Toone, Neil L. Spector, Wayne F. Beyer, Jr., Harold Walder
  • Publication number: 20160221934
    Abstract: Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R21, R22, R23, R34, R37, R33, R39, D, Q, Y, X, X1, X3, and X4 are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: August 4, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20160200673
    Abstract: Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, Y, Z, X, R12, R17, R18, R19, Y1, Z1, X1, and X2 are defined herein. These compounds are useful for treating Gram-negative bacteria infections, such as Neisseria gonorrhoeae bacterial infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Publication number: 20160200682
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Application
    Filed: August 18, 2014
    Publication date: July 14, 2016
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Patent number: 9260382
    Abstract: A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a compound described herein.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: February 16, 2016
    Assignees: UWM Research Foundation, Duke University
    Inventors: Ching-Hong Yang, Xin Chen, Eric J. Toone
  • Publication number: 20150202294
    Abstract: Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
    Type: Application
    Filed: January 23, 2015
    Publication date: July 23, 2015
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Wenle XIA, David GOODEN, Erik J. SODERBLOM, Eric J. TOONE, Neil L. SPECTOR, Wayne F. BEYER, JR., Harold WALDER